· ZüpMed · Weight Loss & Metabolic Health · 1 min read
The Good News About The New Weight Loss Meds
Discussing semaglutide and tirzepatide—their potential for preventative medicine rather than just treating symptoms after conditions develop.
Overview
This blog post discusses emerging weight loss medications, specifically semaglutide and tirzepatide, and their potential for preventative medicine rather than treating symptoms after conditions develop.
The Problem
Over 40% of U.S. adults are obese, leading to interconnected cardiometabolic risks including high blood pressure, insulin resistance, elevated cholesterol, and chronic inflammation. These conditions often go untreated until they cause irreversible damage.
The Solution
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) work by mimicking glucagon-like peptide 1 receptors, reducing appetite and promoting satiety. When combined with diet and exercise, they produce substantial weight loss.
Clinical Results
ZüpMed reported a 70% reversal of prediabetes diagnoses in patients taking these medications within months.
Why ZüpMed
We emphasize the importance of FDA-approved formulations over compounded versions and highlight our holistic monitoring approach, which tracks cardiometabolic markers and can reduce the need for additional medications like blood pressure drugs.
Insurance
Our practice works to optimize treatment options regardless of insurance coverage through expert pharmacist consultation.
ZüpMed’s approach is “intentionally different medical care” emphasizing prevention over reactive treatment.
